https://www.cnbc.com/2022/07/08/long-covid-us-scientists-to-enroll-40000-in-1point2-billion-study-.html

Great article reviewing the response to the pressing need for a long-covid treatment and the NIH's involvement.

The contributors to this article are on their knees, pleading for a phone call from a company like  Resverlogix.   Unfortuantely, I'll bet that these scientists and professors have never heard from us or heard of Apabetalone.   So odd that the company can't speak up and be heard, or believed...  Apabetalone answers their desperate plea for investment in innovation.  Highlighted below. 

The NIH is helping Zenith with a large array of trials, right?  Where's the NIH for Resverlogix on CVD and Long-Covid?    

"Putrino said NIH-funded research is usually slow, risk averse and normally doesn’t lead to rapid implementation of treatments that help patients. He said NIH typically doesn’t invest in high-risk research because it doesn’t want to be perceived as gambling with taxpayer money. Putrino said his team applied for a Recover grant in December 2021 and haven’t heard back yet.

He said NIH should act more like industry by moving quickly to invest in high-risk research that can lead to disruptive innovations.

“The NIH has the capacity to follow a process similar to industry — it’s not typical but they can do it,” said Putrino, who was one of the authors on the March report that criticized the pace of the federal government’s long Covid efforts. “We need a high-risk investment right now,” he said.

In April, President Biden directed Health and Human Services Secretary Xavier Becerra to develop a national research action plan on long Covid in collaboration with the secretaries of Defense, Labor, Energy and Veterans Affairs. HHS is supposed to have the plan ready next month, according to Biden’s directive.

JD Davids, a patient advocate, said the NIH should model the federal response on long Covid after its success in researching and developing HIV treatments. That includes creating a central office at NIH with budgetary authority, similar to the Office of Aids Research, that develops a strategy every year with input from patients on how to use funds for research, said Davids, a member of the Patient-Led Research Collaborative.

Koroshetz and Gibbons said Recover is moving as quickly as possible to get clinical trials on treatments started. “We’re not going to wait four years and then do the trials. We’re going to whatever rises to the top in terms of ideas,” Koroshetz said."

Somebody re-queue the "Resverlogix H.O. Crickets" soundtrack.